Eli Lilly reported that its weight-loss portfolio generated $10 billion in revenue during the most recent quarter, marking the fastest ramp for any drug franchise in company history. This performance reflects an over 80% sequential increase in prescriptions for its leading GLP-1 therapy, driven by expanded insurance coverage and new formulary additions across major U.S. commercial payers. Management noted that patient demand remains strong, with active prescriptions exceeding 500,000 as of quarter end. Investors will be watching payer negotiations and supply-chain efficiencies closely, as Lilly aims to sustain mid-30% annual growth in this segment through 2026.

Eli Lilly and Nvidia have committed $1 billion to establish a joint AI innovation lab focused on accelerating early-stage drug discovery and development. By combining Lilly’s molecular biology expertise with Nvidia’s GPU-powered AI platform, the partners expect to reduce the typical candidate identification timeline by up to 50%. The lab will be staffed by teams in both Indianapolis and Santa Clara, California, and aims to develop at least five AI-designed drug candidates over the next three years. Analysts believe this collaboration could enhance Lilly’s R&D productivity, potentially adding $3 billion in incremental operating profit by 2030.

Eli Lilly has agreed to acquire privately-held Ventyx Biosciences in a deal valued at $4.5 billion, gaining exclusive rights to a phase II oncology asset targeting KRAS G12C mutations. Ventyx’s lead candidate demonstrated a 60% overall response rate in early clinical trials for non-small cell lung cancer, prompting Lilly to anticipate a regulatory filing by late 2026. The transaction includes up to $1.2 billion in milestone payments tied to clinical and commercial milestones. Wall Street strategists suggest the deal enhances Lilly’s mid-stage pipeline resilience and could drive a 5% boost in revenue from oncology by 2028.